Molekulargenetische Diagnostik
Praxis Dr. Mato Nagel

Hepatozyten-Wachstumsfaktor-Rezeptor

Das MET-Gen kodiert eine Tyrosinkinaserezeptor, der wenn an an Hepatozytenwachstumsfaktor gebunden eine wichtige Rolle beim Zellüberleben, Embryogenese, Migration und Invassion spielt. Mutationen werden bei verschiedenen Tumoren gesehen: papilläres Nierenzellkarzinom, hepatozelluläres Karzinom und verschiedene weitere Tumoren im Kopf- und Hals-Bereich.

Diagnostik:

Clinic Untersuchungsmethoden Familienuntersuchung
Bearbeitungszeit 5
Probentyp genomic DNA
Research Untersuchungsmethoden Multiplex ligationsabhängige Amplifikation
Bearbeitungszeit 25
Probentyp genomic DNA
Clinic Untersuchungsmethoden Direkte Sequenzierung der proteinkodierenden Bereiche eines Gens
Bearbeitungszeit 25
Probentyp genomic DNA
Clinic Untersuchungsmethoden Hochdurchsatz-Sequenzierung
Bearbeitungszeit 25
Probentyp genomic DNA

Krankheiten:

Erbliche Schwerhörigkeit 97
MET
Hepatozelluläres Karzinom
MET
Hereditäres papilläres Nierenzellkarzinom 1
MET
Osteofibröse dysplasie
MET

Referenzen:

1.

Beals RK et. al. (1976) Familial congenital bowing of the tibia with pseudarthrosis and pectus excavatum: report of a kindred.

[^]
2.

None (1992) The met oncogene: from detection by transfection to transmembrane receptor for hepatocyte growth factor.

[^]
3.

Bottaro DP et. al. (1991) Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product.

[^]
4.

Park M et. al. (1987) Sequence of MET protooncogene cDNA has features characteristic of the tyrosine kinase family of growth-factor receptors.

[^]
5.

Dean M et. al. (1987) Chromosomal localization of the met proto-oncogene in the mouse and cat genome.

[^]
6.

Dean M et. al. () The human met oncogene is related to the tyrosine kinase oncogenes.

[^]
7.

Cooper CS et. al. () Molecular cloning of a new transforming gene from a chemically transformed human cell line.

[^]
8.

Maina F et. al. (1996) Uncoupling of Grb2 from the Met receptor in vivo reveals complex roles in muscle development.

[^]
9.

Schmidt L et. al. (1997) Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas.

[^]
10.

Sunkara UK et. al. (1997) Bilateral osteofibrous dysplasia: a report of two cases and review of the literature.

[^]
11.

Jeffers M et. al. (1997) Activating mutations for the met tyrosine kinase receptor in human cancer.

[^]
12.

Giordano S et. al. (1997) A point mutation in the MET oncogene abrogates metastasis without affecting transformation.

[^]
13.

Schmidt L et. al. (1998) Two North American families with hereditary papillary renal carcinoma and identical novel mutations in the MET proto-oncogene.

[^]
14.

Zhuang Z et. al. (1998) Trisomy 7-harbouring non-random duplication of the mutant MET allele in hereditary papillary renal carcinomas.

[^]
15.

Jeffers M et. al. (1998) The mutationally activated Met receptor mediates motility and metastasis.

[^]
16.

Park WS et. al. (1999) Somatic mutations in the kinase domain of the Met/hepatocyte growth factor receptor gene in childhood hepatocellular carcinomas.

[^]
17.

Shen Y et. al. (2000) InIB-dependent internalization of Listeria is mediated by the Met receptor tyrosine kinase.

[^]
18.

Powell EM et. al. (2001) Hepatocyte growth factor/scatter factor is a motogen for interneurons migrating from the ventral to dorsal telencephalon.

[^]
19.

Maina F et. al. (2001) Coupling Met to specific pathways results in distinct developmental outcomes.

[^]
20.

Giordano S et. al. (2002) The semaphorin 4D receptor controls invasive growth by coupling with Met.

[^]
21.

Carrolo M et. al. (2003) Hepatocyte growth factor and its receptor are required for malaria infection.

[^]
22.

Boccaccio C et. al. (2005) The MET oncogene drives a genetic programme linking cancer to haemostasis.

[^]
23.

Veiga E et. al. (2005) Listeria hijacks the clathrin-dependent endocytic machinery to invade mammalian cells.

[^]
24.

Karol LA et. al. (2005) Familial osteofibrous dysplasia. A case series.

[^]
25.

Campbell DB et. al. (2006) A genetic variant that disrupts MET transcription is associated with autism.

[^]
26.

Engelman JA et. al. (2007) MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.

[^]
27.

Zou C et. al. (2007) Lack of Fas antagonism by Met in human fatty liver disease.

[^]
28.

Kaushansky A et. al. (2011) The crucial role of hepatocyte growth factor receptor during liver-stage infection is not conserved among Plasmodium species.

[^]
29.

Rodgers JT et. al. (2014) mTORC1 controls the adaptive transition of quiescent stem cells from G0 to G(Alert).

[^]
30.

Mujtaba G et. al. (2015) A mutation of MET, encoding hepatocyte growth factor receptor, is associated with human DFNB97 hearing loss.

[^]
31.

Finisguerra V et. al. (2015) MET is required for the recruitment of anti-tumoural neutrophils.

[^]
32.

Gray MJ et. al. (2015) Mutations Preventing Regulated Exon Skipping in MET Cause Osteofibrous Dysplasia.

[^]
Update: 26. September 2018

 

Die Seite verwendet Cookies, um Ihnen den bestmöglichen Service zu gewährleisten. Bitte bestätigen Sie uns kurz per Klick, dass Sie mit der Nutzung von Cookies einverstanden sind: